New keytruda copycat tested for melanoma prevention
Disease control
Not yet recruiting
This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…
Phase: PHASE1 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC